Roche and Bayer Schering Pharma have been publically reprimanded for bringing discredit upon the UK pharma industry.Bayer fell foul of …
Health minister Lord Darzi has unveiled proposals that would see the NICE appraisal process speeded up considerably. NICE has been …
Awareness, persuasion and emotional appeal are all important factors in effective advertising. The key is to draw attention to the …
The market for contract manufacturing of prescription drugs exceeded $30 billion last year, a 10% increase that is being fuelled …
Bayer Schering Pharma's plan to build a 100 million-euro R&D centre in Beijing marks the company's first major foray into …
There can be all sorts of reasons to work from home, from the usual, such as fitting work around the …
Novartis has recalled UK supplies of its meningitis C vaccine after tests found some batches contaminated with bacteria. The recall …
Spanish pharma company Almirall is in discussions with potential partners for one of its asthma drugs following positive trial results. …
The pharma industry's current sales and marketing model will be defunct in the next ten years. That is the stark …
London-based healthcare PR specialist Virgo Health has won the UK account for new diabetes drug Onglyza. Due to be launched …
Lilly and Daiichi Sankyo have won European approval for their blood-thinning drug Efient, which will go up against established blockbuster …
The battle for the future of Genentech has heated up after the company's board asked its shareholders to reject Roche's …
Biologics company NovaBiotics has been dubbed a Rising Star for 2009 by the Scottish arm of the BioIndustry Association. The …
With the election of Barack Obama, widespread changes are anticipated for US healthcare and ultimately for the pharmaceutical industry. Although …
The world is getting bigger and smaller at the same time. When the internet began to really catch on about …
Roche has been allowed to rejoin the ranks of the ABPI, after its six-month suspension for bringing discredit on the …
Shire has bought the global rights for two established treatments for Attention Deficit Hyperactivity Disorder from UCB. The acquisition gives …